Histogen
Ms. Knudson brings over 20 years of public and private experience in finance, corporate strategy, and operations in the life sciences industry to Histogen. Prior to joining Histogen, Susan was Chief Financial Officer of Pfenex Inc. where she successfully led fund raising efforts and executing on strategies to grow the business from development stage through commercialization.
From 2014 to 2017 Susan was the Chief Financial Officer of Neothetics Inc. where she lead the company’s strategic and corporate finance activities from pre-IPO through and IPO raising over $160M. Prior to joining Neothetics, Ms. Knudson served as the Sr. Director of Finance and Administration at Avera Pharmaceuticals, where she spearheaded the Company’s financing strategy, raising over $90 million in venture capital, and was an integral part of the in-licensing of the Company’s lead drug candidates from large, multinational pharmaceutical companies. Susan also held senior positions at MD Edge, Ionis Pharmaceuticals and CombiChem. Susan currently serves on the board of directors of Freedom Dogs. Ms. Knudson holds a B.A in Accounting from the University of San Diego.
This person is not in any offices
Histogen
Histogen is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.